The growing evidence that tumors can evade the immune system through a variety of mechanisms makes understanding these processes critical to implementing new and more effective forms of immunotherapy. In Cancer Immunotherapy at the Crossroads: How Tumors Evade Immunity and What Can Be Done, leading investigators and clinicians detail the different mechanisms used by tumors to escape and impair the immune system and then spell out possible clinical strategies to prevent or reverse tumor-induced immune dysfunction. The authors review the mechanisms of immune dysfunction and evasion mechanisms in histologically diverse human tumors, focusing on tumor-induced molecular defects in T cells and antigen-presenting cells (dendritic cells and tumors) that may serve as biomarkers for patient prognosis. They discuss the means by which immune functions may be protected or restored in order to more effectively support the process of tumor rejection in situ. Cutting-edge techniques with the capacity to monitor the strength and quality of patients' immune responses using immunocytometry, MHC-peptide tetramers combined with apoptosis assay, ELISPOT assay, and detection of MHC-TAA peptide complexes on tumor cells are also outlined.
State-of-the-art and insightful, Cancer Immunotherapy at the Crossroads: How Tumors Evade Immunity and What Can Be Done illuminates the possibilities for developing effective immunotherapies that can block the mechanisms by which tumors evade the immune system in different histologic types of tumors.

Klappentext

Leading investigators and clinicians detail the different mechanisms used by tumors to escape and impair the immune system and then spell out possible clinical strategies to prevent or reverse tumor-induced immune dysfunction. The authors review the mechanisms of immune dysfunction and evasion mechanisms in histologically diverse human tumors, focusing on tumor-induced molecular defects in T cells and antigen-presenting cells (dendritic cells and tumors), that may serve as biomarkers for patient prognosis. They discuss the means by which these immune functions may be protected or restored in order to more effectively support the process of tumor rejection in situ. Cutting-edge techniques are outlined with the capacity to monitor the strength and quality of patients' immune responses using immunocytometry, MHC-peptide tetramers combined with apoptosis assay, ELISPOT assay, and detection of MHC-TAA peptide complexes on tumor cells.

Inhalt

Part I. Basic Mechanisms of Immune Evasion HLA Class I Antigen-Processing Machinery and HLA Class I Antigen-Derived Peptide-Complex Defects in Tumor-Cell Escape Michael Campoli, Chien-Chung Chang, Xin-Hui Wang, and Soldano Ferrone Immune Defects in T Cells From Cancer Patients: Parallels in Infectious Diseases Augusto C. Ochoa, Paulo C. Rodriguez, Jovanny Zabaleta, Pelayo Correa, and Arnold H. Zea Malfunction of the Dendritic Cell System in Cancer Zoya R. Yurkovetsky, Irina L. Tourkova, Levent Balkir, Lori Perez, Galina V. Shurin, Gurkamal S. Chatta, and Michael R. Shurin CD4+ T-Cell-Mediated Immunity to Cancer Tomohide Tatsumi, Amy Wesa, James H. Finke, Ronald M. Bukowski, and Walter J. Storkus Immunological Ignorance in Cancer Koji Tamada and Lieping Chen The Role of Receptor-Mediated Apoptosis in T-Cell Dysfunction Hannah Rabinowich and Brian R. Gastman Alterations in T-Cell Signaling Pathways and Increased Sensitivity to Apoptosis Ithaar H. Derweesh, Luis Molto, Charles Tannenbaum, Patricia Rayman, Christina Moon, Cynthia Combs, Thomas Olencki, Paul Elson, Ronald M. Bukowski, and James H. Finke The Role of Tumor Gangliosides in the Immune Dysfunction of Cancer Stephan Ladisch Interleukin-10-Induced Immune Suppression in Cancer Arvin S. Yang and Edmund C. Lattime Accentuating Tumor Immunity Through Costimulation: A Detailed Analysis of OX40 Engagement and CTLA-4 Blockade Andrew D. Weinberg, Dean E. Evans, and Arthur A. Hurwitz Optimizing T-Cell Adoptive Immunotherapy to Overcome Tumor Evasion Peter A. Cohen, Gregory E. Plautz, James H. Finke, and Suyu Shu Tumor Resistance to Apoptosis: Mechanisms of Evasion and Implications for Radiation and Chemotherapeutic Strategies Robert G. Uzzo, Paul Cairns, Nickolai Dulin, Eric M. Horwitz, Alan Pollack, and Vladimir Kolenko Part II. Clinical Relevance of Immune Evasion The Development and Reversal of T-Cell Tolerance in Cancer Patients Receiving Peptide-Based Vaccines Ena Wang and Francesco M. Marincola Altered Signaling in T Lymphocytes of Patients With Cancer: A Biomarker of Prognosis? Theresa L. Whiteside Allogeneic Hematopoietic Blood-Cell Transplantation as Immunotherapy for Metastatic Renal Cell Carcinoma Richard W. Childs and Cristian A. Carvallo Immune Defects in Patients Suffering From Non-Hodgkin's Lymphoma Thomas Zander, Daniel Re, Michael von Bergwelt-Baildon, Jürgen Wolf, and Joachim L. Schultze Immune Dysfunction in Classical Hodgkin's Lymphoma Arjan Diepstra, Ewerton M. Maggio, Anke van den Berg, and Sibrand Poppema Lung Cancer and Immune Dysfunction Steven M. Dubinett, Sherven Sharma, Min Huang, Jenny T. Mao, and Raj K. Batra Primary Malignant Brain Tumors: Immune Defects and Immune Evasion Lucinda H. Elliott, Lorri A. Morford, William H. Brooks, and Thomas L. Roszmam Index